APIs &
CDMO business

J2H Biotech Pharmaceutical Business Division was established in November 2020 and received GMP approval from the Korea Ministry of Food and Drug Safety in June 2022, focusing on manufacturing and quality control of high-value APIs.

We focus on developing various types of incrementally modified drug (IMD) APIs such as IMD APIs, novel crystalline salts, and pharmaceutical cocrystals for patent registration and are developing exclusive supply of APIs per client’s request.

We provide CDMO business upon customer’s needs such as high-yield & high-purity API development, patentable API development, new drug candidate synthesis, and CMC documentation.